This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Ucb Biopharma Sprl. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Gillian Sairfull Watt: Innovator in Biomarker Research
Introduction
Gillian Sairfull Watt is a prominent inventor based in Luton, GB. She has made significant contributions to the field of biomarker research, particularly in relation to IL-17 mediated diseases. Her innovative work has the potential to enhance therapeutic strategies for patients undergoing anti-IL-17 therapy.
Latest Patents
Gillian holds a patent titled "Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy." This invention provides the use of lipocalin 2 (LCN2) as a biomarker for monitoring the response of patients to anti-IL-17 therapy. This advancement is crucial for improving treatment outcomes in patients suffering from IL-17 mediated diseases.
Career Highlights
Gillian is currently associated with UCB Biopharma Sprl, where she continues to push the boundaries of research and innovation. Her work is characterized by a commitment to developing effective biomarkers that can significantly impact patient care.
Collaborations
Gillian collaborates with esteemed colleagues, including Adam Samuel Platt and Stephen Edward Rapecki. These partnerships enhance her research efforts and contribute to the advancement of biomarker applications in clinical settings.
Conclusion
Gillian Sairfull Watt is a trailblazer in the field of biomarker research, with her patent on lipocalin 2 showcasing her innovative spirit. Her contributions are paving the way for improved therapeutic strategies in the treatment of IL-17 mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile